Samad Sam, the Executive Vice President and Chief Financial Officer of Quest Diagnostics Inc, made a notable investment in the company by acquiring 90 shares of common stock on October 21, 2026. This transaction, reported in a recent SEC filing, brings his total ownership to 33,568 shares.

This acquisition is significant as it demonstrates Sam's confidence in the company's future prospects. Insider purchases can often be seen as a positive signal to investors and the market, indicating that executives believe in the long-term value of their company.

Background

Quest Diagnostics Inc operates in the medical laboratories sector, specifically classified under the SIC code 8071. The company is incorporated in Delaware and has its headquarters in Secaucus, New Jersey. Quest Diagnostics is a leading provider of diagnostic information services, offering a wide range of tests and services to healthcare providers and patients.

In recent filings, Samad Sam has consistently reported transactions under Form 4, with the latest being filed on October 23, 2026. Other recent filings include transactions from July and May of the same year, indicating ongoing activity in his stock ownership.

What the Filing Says

The filing states that the transaction was executed at a price of $235.939 per share. It notes that the shares were acquired through a dividend reinvestment plan administered by Samad's broker, which allows for the automatic reinvestment of dividends into additional shares. The filing specifies that this transaction is eligible for deferred reporting on Form 5 under Rule 16a-6, but Samad chose to report it early on Form 4.

Impact

This acquisition may influence both shareholders and potential investors in Quest Diagnostics. Insider buying can lead to increased investor confidence, as it suggests that company executives are optimistic about the future performance of their organization. Additionally, this move could prompt similar actions from other executives within the medical laboratories sector, potentially leading to a trend of increased insider buying.

What's Next

The filing does not say what happens next. Investors and market watchers will likely keep an eye on further transactions from Samad and other executives at Quest Diagnostics to gauge sentiment about the company's performance.